Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30955208 | 1.00 | NPC1 (0.42) | NPC1RAB9AFDFT1LMNASMN1; SMN2 | |
| SCHEMBL27435742 | 0.85 | EGLN1 (0.44) | NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL29480725 | 0.84 | FDFT1 (0.34) | NPC1RAB9AFDFT1CHRNB2CHRNA4 | |
| SCHEMBL22736214 | 0.84 | FDFT1 (0.34) | NPC1RAB9AFDFT1CHRNB2CHRNA4 | |
| SCHEMBL14966201 | 0.82 | FDFT1 (0.33) | NPC1RAB9AFDFT1CHRNB2CHRNA4 | |
| SCHEMBL11905760 | 0.82 | ADRB2 (0.41) | NPC1RAB9AFDFT1CHRNB2CHRNA4 | |
| SCHEMBL31065707 | 0.82 | FDFT1 (0.33) | NPC1RAB9AFDFT1CHRNB2CHRNA4 | |
| SCHEMBL12614358 | 0.82 | ADRB2 (0.41) | NPC1RAB9AFDFT1CHRNB2CHRNA4 | |
| SCHEMBL1241173 | 0.82 | FDFT1 (0.37) | NPC1RAB9AFDFT1LMNASMN1; SMN2 | |
| SCHEMBL18489402 | 0.82 | FDFT1 (0.37) | NPC1RAB9AFDFT1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242565-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF IN THE PREVENTION OR THERAPY OF DISEASES | Samsara Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4653432-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF IN THE PREVENTION OR THERAPY OF DISEASES | Samsara Therapeutics Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12435054-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4612140-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | Captor Therapeutics S.A. (PL) | 2025-09-10 | — | — | EP | disclosed |
| EP-3589628-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-115991721-B | Phosphine-containing compound, preparation method thereof and application of phosphine-containing compound as ligand of ethylene oligomerization catalyst composition | 中化学科学技术研究有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4185386-B1 | HETEROCYCLIC INHIBITORS OF TEAD FOR TREATING CANCER | GENENTECH INC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024133499-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) | 2024-06-27 | — | — | WO | disclosed |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| CN-102448960-A | Derivatives of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-carboxylic acid amides | BOEHRINGER INGELHEIM INT | 2012-05-09 | — | — | CN | disclosed |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100087382-A1 | Inhibitors of Hepatitis C NS3 Protease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-08 | — | — | US | disclosed |
| WO-2009117421-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117421-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087382-A1 | Inhibitors of Hepatitis C NS3 Protease | RNASE1, GTF3C3, CTRL | NPC1 491/4885RAB9A 1251/4885FDFT1 3156/4885 |
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | NPC1 660/4885RAB9A 2246/4885FDFT1 1368/4885 |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, NQO1, PCSK9 | NPC1 16/4885RAB9A 601/4885FDFT1 710/4885 |
| US-12435054-B2 | Therapeutic compounds and methods of use | VHL, NQO1, PCSK9 | NPC1 16/4885RAB9A 601/4885FDFT1 710/4885 |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | STS, ARSA, TST | NPC1 3220/4885RAB9A 2937/4885FDFT1 134/4885 |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | NPC1 488/4885RAB9A 2087/4885FDFT1 641/4885 |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | NPC1 3951/4885RAB9A 2364/4885FDFT1 1991/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | NPC1 3951/4885RAB9A 2364/4885FDFT1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.